Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.87 USD

35.87
3,167,156

+0.17 (0.48%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Why the Earnings Surprise Streak Could Continue for Baxter (BAX)

Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

What Makes Baxter (BAX) a New Buy Stock

Baxter (BAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Can Core Renal Care Unit Drive Baxter's (BAX) Q1 Earnings?

Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.

Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Invest in Baxter International Now

Baxter (BAX) teams up with bioMerieux to treat acute kidney injury.

Baxter Showcases PN Product Portfolio at ASPEN Conference

The launch of Clinolipid will be a crucial step toward Baxter's (BAX) goal of strengthening its lipid portfolio and offering enhanced health care to malnourished patients.

Moving Average Crossover Alert: Baxter International

Baxter International Inc. (BAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Fresenius Medical's New Hemodialysis Software Gets FDA Nod

Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.

Baxter (BAX) Soars to 52-Week High, Time to Cash Out?

Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Moving Average Crossover Alert: Baxter International

Baxter International Inc. (BAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Baxter (BAX) Upgraded to Buy: Here's What You Should Know

Baxter (BAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Baxter's (BAX) New Tie Up to Boost Acute Therapies Business

Baxter's (BAX) Acute Therapies business is expected to grow 7-8% in 2019.

Mark Vickery headshot

Top Analyst Reports for Home Depot, Oracle & Union Pacific

Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Oracle (ORCL) and Union Pacific (UNP).

Baxter (BAX) Gets FDA Approval for Eptifibatide to Treat ACS

Baxter's (BAX) Eptifibatide is a platelet aggregation inhibitor that prevents platelets-specialized blood cells clotting.

Baxter's Acute Therapies Profile Strong, Competition Rife

Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.

Baxter's (BAX) Earnings, Revenues Beat Estimates in Q4

Baxter (BAX) gains from the Renal Care and Advanced Surgery units in fourth-quarter 2018; Clinical Nutrition revenues soft.

Baxter International (BAX) Q4 Earnings and Revenues Surpass Estimates

Baxter (BAX) delivered earnings and revenue surprises of 6.85% and 1.45%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Medical Products' Earnings Lineup for Jan 31: EW, BAX & More

Let's take a look at the factors that are likely to influence the earnings results of a few Medical Products bigwigs within the broader Medical space.

Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?

Becton, Dickinson's (BDX) solid fiscal first-quarter preliminary results boost optimism in the stock.

Baxter International (BAX) Reports Next Week: Wall Street Expects Earnings Growth

Baxter (BAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Core Renal Care Unit Fuel Baxter's (BAX) Q4 Earnings?

Management at Baxter (BAX) expects Renal Care to see growth of 3-4% in 2018.

Will Core MedSurg Segment Aid Stryker's (SYK) Q4 Earnings?

Stryker's (SYK) Q4 results are likely to be aided by its core MedSurg segment.

Stock Market News For Jan 18, 2019

Benchmarks ended in the green on Thursday, extending the streak of gains to three days on the trot.

Baxter (BAX) Gains From Sharesource's Global Success Rates

Baxter's (BAX) PD platform sees increased demand, owing to rising CKD rates around the world.

Will Instruments Fuel Intuitive Surgical (ISRG) Q4 Earnings?

Intuitive Surgical's (ISRG) top line in the fourth quarter of 2018 is likely to benefit from solid grow that the Instruments and Accessories segment.